Characteristics of study population
| Methacholine hyperresponsiveness | p Value | |||
|---|---|---|---|---|
| All subjects | Positive | Negative | ||
| N (male) | 58 (36) | 23 (13) | 35 (23) | NS |
| Age, mean (SD), years | 18.1 (1.7) | 17.9 (2.0) | 18.2 (1.4) | NS |
| Height, mean (SD), cm | 174.8 (8.7) | 171.8 (8.7) | 176.7 (8.2) | 0.04 |
| Weight, mean (SD), kg | 65.7 (10.4) | 63.0 (10.7) | 67.5 (9.9) | NS |
| Weekly training, mean (SD), h | 11.7 (2.6) | 11.3 (1.9) | 12.0 (3.0) | NS |
| Competitive experience, mean (SD), years | 8.2 (2.4) | 8.1 (2.7) | 8.3 (2.1) | NS |
| Self-reported allergy | 16 (27%) | 8 (35%) | 8 (23%) | NS |
| Positive AlaTOP screen | 20 (35%) | 11 (48%) | 9 (26%) | NS |
| Asthma-like symptomatology | 26 (45%) | 7 (30%) | 19 (54%) | NS |
| Doctor-diagnosed asthma | 10 (17%) | 4 (17%) | 6 (17%) | NS |
| Medication within past 12 months | 19 (33%) | 6 (26%) | 13 (37%) | NS |
| β2 Agonist | 11 (20%) | 6 (26%) | 5 (14%) | NS |
| Inhaled corticosteroids | 6 (10%) | 2 (9%) | 4 (11%) | NS |
| Antihistamines | 2 (3%) | 0 (0%) | 2 (6%) | NS |